Effect of microrna-138 on epithelial-Mesenchymal transition and invasion of breast cancer cells by targeting semaphorin 4C

References

• Mangone L, Ferrari F, Mancuso P. Epidemiology and biological characteristics of male breast cancer in Italy. Breast Cancer. 2020;27(4):724–731.
   PubMed Web of Science ®Google Scholar
• Spronk I, Schellevis FG, Burgers JS. Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review. Breast. 2018;39:70–79.
   PubMed Web of Science ®Google Scholar
• Liu KH, Zhang L, Chen JX. Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: a SEER database study. Breast. 2020;49:233–241.
   PubMed Web of Science ®Google Scholar
• Narui K, Ishikawa T, Shimizu D. Anthracycline could be essential for triple-negative breast cancer: a randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. Breast. 2019;47:1–9.
   PubMed Web of Science ®Google Scholar
• Langer EM, Kendsersky ND, Daniel CJ. ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene. 2018;37(8):1005–1019.
   PubMed Web of Science ®Google Scholar
• Zhang HD, Jiang LH, Sun DW. miR-30a inhibits the biological function of breast cancer cells by targeting Notch1. Int J Mol Med. 2017;40(4):1235–1242.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Fan X, Jiang L. miR-503-3p promotes epithelial-mesenchymal transition in breast cancer by directly targeting SMAD2 and E-cadherin. J Genet Genomics. 2017;44(2):75–84.
   PubMed Web of Science ®Google Scholar
• Lu J, Lin Y, Li F. MiR-205 suppresses tumor growth, invasion, and epithelial–mesenchymal transition by targeting SEMA4C in hepatocellular carcinoma. The FASEB J. 2018;32(1):1–13
   PubMedGoogle Scholar
• Song J, Li Y. miR-25-3p reverses epithelial-mesenchymal transition via targeting SEMA4C in cisplatin-resistance cervical cancer cells. Cancer Sci. 2017;108(1):23–31.
   PubMed Web of Science ®Google Scholar
• Pastushenko I, Brisebarre A, Sifrim A. Identification of the tumour transition states occurring during EMT. Nature. 2018;556(7702):463–468.
   PubMed Web of Science ®Google Scholar
• Segovia-Mendoza M, Romero-Garcia S, Lemini C. Determining factors in the therapeutic success of checkpoint immunotherapies against PD-L1 in breast cancer: a focus on epithelial-mesenchymal transition activation. J Immunol Res. 2021;2021:6668573.
   PubMed Web of Science ®Google Scholar
• Li J, Wang Q, Wen R. MiR-138 inhibits cell proliferation and reverses epithelial-mesenchymal transition in non-small cell lung cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med. 2015;19(12):2793–2805.
   PubMed Web of Science ®Google Scholar
• Wang S, Gao G, He Y, et al. Amidation-Modified Apelin-13 regulates PPARγ and perilipin to inhibit adipogenic differentiation and promote lipolysis. Bioinorg Chem Appl. 2021;2021:3594630.
   PubMed Web of Science ®Google Scholar
• Yu Y, Luo W, Yang ZJ. miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial-mesenchymal transition. Mol Cancer. 2018;17(1):70–73.
   PubMed Web of Science ®Google Scholar
• Malmgren JA, Calip GS, Atwood MK. Metastatic breast cancer survival improvement restricted by regional disparity: surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011. Cance. 2020;126(2):390–399.
   PubMed Web of Science ®Google Scholar
• Loh CY, Chai JY, Tang TF. The E-Cadherin and N-Cadherin switch in epithelial-to-mesenchymal transition: signaling, therapeutic implications, and challenges. Cells. 2019;8(10):10.
   Web of Science ®Google Scholar
• Segovia-Mendoza M, Romero-Garcia S, Lemini C. Determining factors in the therapeutic success of checkpoint immunotherapies against PD-L1 in breast cancer: a focus on epithelial-mesenchymal transition activation. J Immunol Res. 2021;2021:6668573.
   PubMed Web of Science ®Google Scholar
• Muraleedharan CK, McClellan SA, Ekanayaka SA. The miR-183/96/182 cluster regulates macrophage functions in response to pseudomonas aeruginosa. J Innate Immun. 2019;11(4):347–358.
   PubMed Web of Science ®Google Scholar
• Kovalchuk A, Ilnytskyy Y, Rodriguez-Juarez R. Growth of malignant extracranial tumors alters microRNAome in the prefrontal cortex of TumorGraft mice. Oncotarget. 2017;8(51):88276–88293.
   PubMedGoogle Scholar
• Telonis AG, Rigoutsos I. Race disparities in the contribution of miRNA Isoforms and tRNA-Derived fragments to triple-negative breast cancer. Cancer Res. 2018;78(5):1140–1154.
   PubMed Web of Science ®Google Scholar
• Zhou L, Su X, Li B. PM2.5 exposure impairs sperm quality through testicular damage dependent on NALP3 inflammasome and miR-183/96/182 cluster targeting FOXO1 in mouse. Ecotoxicol Environ Saf. 2019;169:551–563.
   PubMed Web of Science ®Google Scholar
• Guo J, Duan Z, Zhang C. Mouse 4T1 breast cancer cell-derived exosomes induce proinflammatory cytokine production in macrophages via miR-183. J Immunol. 2020;205(10):2916–2925.
   PubMed Web of Science ®Google Scholar
• Kim J. Identification of MicroRNAs as diagnostic biomarkers for breast cancer based on the cancer genome Atlas. Diagnostics (Basel). 2021;11(1):107.
   PubMedGoogle Scholar
• Li Y, Zeng Q, Qiu J. Corrigendum: miR-183-5p promotes proliferation, metastasis and angiogenesis in breast cancer cells through negatively regulating four and a half LIM protein 1. J Breast Cancer. 2020;23(5):576.
   PubMed Web of Science ®Google Scholar
• Hou Y, Wang W, Zeng Z. High SEMA4C expression promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal carcinoma. Aging (Albany NY). 2020;12(21):21992–22018.
   PubMedGoogle Scholar
• Gurrapu S, Pupo E, Franzolin G. SEMA4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential. Cell Death Diffe. 2018;25(7):1259–1275
   PubMed Web of Science ®Google Scholar
• Brabletz T, Kalluri R, Nieto MA. EMT in cancer. Nat Rev Cancer. 2018;18(2):128–134.
   PubMed Web of Science ®Google Scholar
• Liang Z, Feng Q, Xu L. CREPT regulated by miR-138 promotes breast cancer progression. Biochem Biophys Res Commun. 2017;493(1):263–269.
   PubMed Web of Science ®Google Scholar